Hilltop Holdings Inc. Boosts Stock Holdings in AbbVie Inc. $ABBV

Hilltop Holdings Inc. grew its holdings in AbbVie Inc. (NYSE:ABBV) by 4.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 56,279 shares of the company’s stock after purchasing an additional 2,573 shares during the quarter. AbbVie makes up 0.7% of Hilltop Holdings Inc.’s portfolio, making the stock its 22nd biggest position. Hilltop Holdings Inc.’s holdings in AbbVie were worth $13,031,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ABBV. Hollow Brook Wealth Management LLC increased its holdings in AbbVie by 6.2% during the third quarter. Hollow Brook Wealth Management LLC now owns 3,531 shares of the company’s stock valued at $818,000 after buying an additional 206 shares during the period. Gotham Asset Management LLC lifted its holdings in AbbVie by 31.8% during the third quarter. Gotham Asset Management LLC now owns 48,471 shares of the company’s stock worth $11,223,000 after buying an additional 11,698 shares during the period. Fairfield Bush & CO. boosted its position in AbbVie by 2.5% during the 3rd quarter. Fairfield Bush & CO. now owns 6,167 shares of the company’s stock valued at $1,428,000 after acquiring an additional 152 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of AbbVie by 96.6% in the 3rd quarter. Fred Alger Management LLC now owns 110,561 shares of the company’s stock valued at $25,599,000 after acquiring an additional 54,335 shares during the period. Finally, First Western Trust Bank increased its holdings in shares of AbbVie by 1.2% in the 3rd quarter. First Western Trust Bank now owns 4,934 shares of the company’s stock valued at $1,142,000 after acquiring an additional 59 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ABBV shares. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Citigroup cut their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.08% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

AbbVie Trading Down 2.5%

Shares of NYSE ABBV opened at $219.73 on Monday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a 50 day simple moving average of $224.33 and a two-hundred day simple moving average of $224.79. The stock has a market cap of $388.51 billion, a price-to-earnings ratio of 93.10, a PEG ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 earnings per share. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.